TY - JOUR
T1 - Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients
T2 - A preliminary study of JCOG2005 (J-BASE-MARGIN)
AU - Kamimura, Anna
AU - Nakamura, Yasuhiro
AU - Takenouchi, Tatsuya
AU - Matsushita, Shigeto
AU - Omodaka, Toshikazu
AU - Yamamura, Kentaro
AU - Uchi, Hiroshi
AU - Yoshikawa, Shusuke
AU - Yanagisawa, Hiroto
AU - Ito, Takamichi
AU - Kiyohara, Yoshio
AU - Nakamura, Yoshio
AU - Aoki, Megumi
AU - Ishizuki, Shoichiro
AU - Oashi, Kohei
AU - Miyagawa, Takuya
AU - Maeda, Taku
AU - Ogata, Dai
AU - Hatta, Naohito
AU - Ohe, Shuichi
AU - Isei, Taiki
AU - Takahashi, Akira
AU - Umeda, Yoshiyasu
AU - Yamaguchi, Buntaro
AU - Ishikawa, Masashi
AU - Horimoto, Kohei
AU - Fujsawa, Yasuhiro
AU - Uehara, Jiro
AU - Shibayama, Yoshitsugu
AU - Kiniwa, Yukiko
AU - Kawahara, Yu
AU - Matsuya, Taisuke
AU - Uhara, Hisashi
AU - Kato, Junji
AU - Nakamura, Yoshiyuki
AU - Murakami, Takuo
AU - Namikawa, Kenjiro
AU - Yoshino, Koji
AU - Funakoshi, Takeru
AU - Takatsuka, Sumiko
AU - Matsui, Yu
AU - Sasaki, Jin
AU - Koga, Hiroshi
AU - Yokota, Kenji
AU - Komori, Takaya
AU - Fukushima, Satoshi
AU - Yamazaki, Naoya
N1 - Funding Information:
This research was supported by the Japan Agency for Medical Research and Development (AMED) under grant number JP21ck0106681h0001 and JP21ck0106681h0002 and the National Cancer Center Research and Development Funds under grant number 2020‐J‐3. We thank Ms. Sachie Iwaoka and Ms. Tamami Kimura for their assistance with dataset collection.
Funding Information:
Anna Kamimura has received honoraria from Novartis. Yasuhiro Nakamura received institutional research funding from Kaken, Ono Pharma, Pola Pharma, and Torii, and has served as a consultant and/or has received honoraria from Bristol‐Myers Squibb (BMS), Maruho, Merck Sharp & Dohme (MSD), Novartis, Ono Pharma, Taisho Toyama, and Mitsubishi Tanabe Pharma. Tatsuya Takenouchi has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Shigeto Matsushita received institutional research funding from Kaken and Tokiwa Pharma and has served as a consultant and/or has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Hiroshi Uchi has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Shusuke Yoshikawa has received honoraria from Novartis and Ono Pharma. Yoshio Kiyohara has received honoraria from BMS, Novartis, and Ono Pharma. Shoichiro Ishizuki has received honoraria from Novartis. Kohei Oashi has received honoraria from Ono Pharma. Taiki Isei has served as a consultant and/or has received honoraria from Ono Pharma, Pfizer, BMS, and Novartis Pharma. Yoshiyasu Umeda has received honoraria from Novartis and Ono Pharma. Buntaro Yamaguchi has received honoraria from Maruho. Yasuhiro Fujisawa received research funding from Eisai and Ono Pharma and has served as a consultant and/or has received honoraria from BMS, Eli Lilly, Novartis, and Ono Pharma. Yukiko Kiniwa has received honoraria from Novartis and Ono Pharma. Yu Kawahara has received honoraria from Maruho. Hisashi Uhara received institutional research funding from Abbvie, Daiichi Synkyo, Eisai, Kaken Pharmaceutical, Kyowa Kirin, Maruho, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co. Ltd., Nihonkayaku, Ono Pharma, Pola Pharma, Taiho Pharmaceutical, Torii, and Tsumura & Co and has served as a consultant and/or has received honoraria from BMS, Kyowa Kirin, Maruho, MSD, Novartis, Ono Pharma, Pola Pharma, Janssen china R&D, and Mitsubishi Tanabe Pharma. Kenjiro Namikawa has served as a consultant and/or has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Koji Yoshino has served as a consultant and/or has received honoraria from BMS, Novartis, and Ono Pharma. Takeru Funakoshi received research funding from Ono Pharma and has served as a consultant and/or has received honoraria from Ono Pharma. Satoshi Fukushima has received research funding from Ono Pharma and has received honoraria from BMS, Novartis, and Ono Pharma. Naoya Yamazaki received institutional research funding from BMS, MSD, Novartis, Ono Pharma, Takara Bio, Amgen, and Merck Biopharma and has served as a consultant and/or has received honoraria from BMS, MSD, Novartis, and Ono Pharma. The other authors have no conflicts of interest to disclose.
Publisher Copyright:
© 2022 Japanese Dermatological Association.
PY - 2022/9
Y1 - 2022/9
N2 - Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur. Therefore, we analyzed the dermato-oncologists’ concordance in judging the clinical tumor border of basal cell carcinoma. Forty-seven dermato-oncologists (experts: 37; young trainees: 10) participated in this study. The datasets of clinical and dermoscopic photographs of 79 Japanese cases of head and neck basal cell carcinoma were used to determine the concordance in the judgment of clinical tumor border. The probability of the border that was selected more often was used to calculate the rater agreement rate for each dataset. Correct judgment was defined as a more frequently selected border, and the concordance rate of clarity of clinical tumor border for each dermato-oncologist was calculated based on the definition of the correct judgment. A median concordance rate of 85% or higher for all dermato-oncologists was predefined as an acceptable rate for clinical use. Of the 79 datasets, rater agreement rates were 80–100%, 60–79%, and 51–59% for 55, 19, and five datasets, respectively. The median concordance rate for all dermato-oncologists was 86% (interquartile range: 82–89%). There was no significant difference in the concordance rate between the experts and the trainees (median, 87% vs. 85.5%; p = 0.58). The concordance rates of dermato-oncologists for all datasets were relatively high and acceptable for clinical use.
AB - Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur. Therefore, we analyzed the dermato-oncologists’ concordance in judging the clinical tumor border of basal cell carcinoma. Forty-seven dermato-oncologists (experts: 37; young trainees: 10) participated in this study. The datasets of clinical and dermoscopic photographs of 79 Japanese cases of head and neck basal cell carcinoma were used to determine the concordance in the judgment of clinical tumor border. The probability of the border that was selected more often was used to calculate the rater agreement rate for each dataset. Correct judgment was defined as a more frequently selected border, and the concordance rate of clarity of clinical tumor border for each dermato-oncologist was calculated based on the definition of the correct judgment. A median concordance rate of 85% or higher for all dermato-oncologists was predefined as an acceptable rate for clinical use. Of the 79 datasets, rater agreement rates were 80–100%, 60–79%, and 51–59% for 55, 19, and five datasets, respectively. The median concordance rate for all dermato-oncologists was 86% (interquartile range: 82–89%). There was no significant difference in the concordance rate between the experts and the trainees (median, 87% vs. 85.5%; p = 0.58). The concordance rates of dermato-oncologists for all datasets were relatively high and acceptable for clinical use.
UR - http://www.scopus.com/inward/record.url?scp=85129322226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129322226&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.16422
DO - 10.1111/1346-8138.16422
M3 - Article
C2 - 35510662
AN - SCOPUS:85129322226
SN - 0385-2407
VL - 49
SP - 837
EP - 844
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 9
ER -